The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2016

Filed:

Sep. 23, 2013
Applicant:

Los Angeles Biomedical Research Institute AT Harbor-ucla Medical Center, Torrance, CA (US);

Inventors:

John E. Edwards, Jr., Palos Verdes Estates, CA (US);

Scott G. Filler, Rancho Palos Verdes, CA (US);

Donald C. Sheppard, Montreal, CA;

Ashraf S. Ibrahim, Irvine, CA (US);

Yue Fu, Carson, CA (US);

Brad J. Spellberg, Rancho Palos Verdes, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/40 (2006.01); C07K 16/14 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61K 38/16 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 38/16 (2013.01); A61K 39/0002 (2013.01); A61K 39/39575 (2013.01); C07K 14/40 (2013.01); C07K 16/14 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01);
Abstract

Abloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.


Find Patent Forward Citations

Loading…